$7.61
9.99% yesterday
Nasdaq, Nov 15, 10:16 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$7.61
+0.57 8.10% 1M
-1.26 14.21% 6M
-3.64 32.36% YTD
+5.17 211.89% 1Y
-3.55 31.81% 3Y
+6.00 372.67% 5Y
-229.69 96.79% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.85 9.99%
ISIN
US02155H1014
Symbol
ALT
Sector
Industry

Key metrics

Market capitalization $541.26m
Enterprise Value $403.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8,072.20
P/S ratio (TTM) P/S ratio 10,825.20
P/B ratio (TTM) P/B ratio 4.06
Revenue growth (TTM) Revenue growth -81.36%
Revenue (TTM) Revenue $50.00k
EBIT (operating result TTM) EBIT $-99.51m
Free Cash Flow (TTM) Free Cash Flow $-78.12m
Cash position $139.42m
EPS (TTM) EPS $-1.55
P/E forward negative
P/S forward 160,240.00
EV/Sales forward 123,533.33
Short interest 31.37%
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Altimmune, Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Altimmune, Inc. forecast:

Buy
78%
Hold
22%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.05 0.05
82% 82%
100%
- Direct Costs 2.10 2.10
-
4,200%
-2.04 -2.04
-
-4,080%
- Selling and Administrative Expenses 16 16
11% 11%
32,040%
- Research and Development Expense 79 79
17% 17%
158,700%
-97 -97
12% 12%
-194,840%
- Depreciation and Amortization 2.10 2.10
-
4,200%
EBIT (Operating Income) EBIT -100 -100
17% 17%
-199,020%
Net Profit -104 -104
32% 32%
-207,040%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Neutral
GlobeNewsWire
about 10 hours ago
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
Positive
Seeking Alpha
2 days ago
Results from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expected to reach $7.64 billion by 2031. Successful EOP2 meeting with FDA, of Pemvidutide for treatment of patients with obesity, brings about four phase 3 trial initiations in the coming year.
Positive
Seeking Alpha
2 days ago
Altimmune, Inc.'s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6% weight reduction at the highest dose. Altimmune's cash runway is estimated to support operations into 1H2026, ...
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website www.altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today